Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
Anticancer Research|February 11, 2015
Which sequence best protects the heart against trastuzumab and anthracycline toxicity? An electron microscopy study in ratsNeyran Kertmen, Sercan Aksoy, Aysegul Uner, et al.
Anti-Cancer Drugs|January 15, 2019
The frequency and predictors of persistent amenorrhea in premenopausal women with colorectal cancer who received adjuvant chemotherapyTevhide Sahin, Omer Dizdar, Nuriye Ozdemir, et al.
Journal of Endocrinological Investigation|May 6, 2024
Quantitative ultrasound techniques and biochemical markers to assess liver steatosis and fibrosis in newly diagnosed acromegalyM Coskun, H N Sendur, A Babayeva, et al.
American Journal of Clinical Oncology|May 12, 2021
A Phase II Study of the Combination of Oxaliplatin, Capecitabine, and Trastuzumab and Chemoradiotherapy in the Adjuvant Setting in Operated Patients With HER2-positive Gastric or Gastroesophageal Junction Cancer (TOXAG Study): A Turkish Oncology Group StudyHuseyin Abali, Suayib Yalcin, Huseyin C Onal, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 26, 2025
Lenvatinib Plus Pembrolizumab, Pemetrexed, and a Platinum as First-Line Therapy for Metastatic Nonsquamous NSCLC: Phase 3 LEAP-006 StudyRoy S Herbst, Byoung Chul Cho, Caicun Zhou, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 18, 2025
Pembrolizumab plus enzalutamide and androgen deprivation therapy versus placebo plus enzalutamide and androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: the randomized, double-blind, phase III KEYNOTE-991 studyC Gratzke, M Özgüroğlu, A Peer, et al.
European Urology|October 1, 2023
Pembrolizumab with or Without Lenvatinib as First-line Therapy for Patients with Advanced Urothelial Carcinoma (LEAP-011): A Phase 3, Randomized, Double-Blind TrialNobuaki Matsubara, Ronald de Wit, Arjun Vasant Balar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 30, 2024
Association of Tumor Mutational Burden and PD-L1 with the Efficacy of Pembrolizumab with or without Chemotherapy versus Chemotherapy in Advanced Urothelial CarcinomaAude Fléchon, Rafael Morales-Barrera, Thomas Powles, et al.
Clinical and Experimental Dermatology|July 8, 2021
Clinical characteristics, quality of life and risk factors for severity in palmoplantar pustulosis: a cross-sectional, multicentre study of 263 patientsS Sarıkaya Solak, A Kara Polat, S Kilic, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 28, 2024
Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSAE Felip, B C Cho, V Gutiérrez, et al.
Pageof 4